We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-2.61%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$10.7B
AUM Growth
-$733M
Cap. Flow
+$511M
Cap. Flow %
4.78%
Top 10 Hldgs %
33.24%
Holding
188
New
39
Increased
39
Reduced
24
Closed
30

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$452M
2
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$186M
3
CMMB
Chemomab Therapeutics
CMMB
+$128M
4
HAE icon
Haemonetics
HAE
+$105M
5
IRON icon
Disc Medicine
IRON
+$86.6M

Top Sells

Rank Stock Value
1
PRLD icon
Prelude Therapeutics
PRLD
+$369M
2
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$319M
3
PFE icon
Pfizer
PFE
+$133M
4
BIIB icon
Biogen
BIIB
+$121M
5
CNC icon
Centene
CNC
+$120M

Sector Composition

Rank Sector Weight
1 Healthcare 94.88%
2 Technology 0.12%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
101
Gilead Sciences
GILD
$166B
$18.6M 0.17%
287,600
+95,400
+50% +$6.15M
VTGN icon
102
VistaGen Therapeutics
VTGN
$9.93M
$18.3M 0.17%
286,800
+36,800
+15% +$2.46M
LKFT
103
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$17.8M 0.17%
+230,905
New +$21.3M
ALHC icon
104
Alignment Healthcare
ALHC
$3.81B
$17.5M 0.16%
+800,000
New +$15.6M
PHGE icon
105
BiomX
PHGE
$1.96M
$16.5M 0.15%
12,176
– –
ALXN
106
DELISTED
Alexion Pharmaceuticals
ALXN
$15.6M 0.15%
102,100
-66,900
-40% -$10.3M
BLU
107
DELISTED
BELLUS Health Inc.
BLU
$15.1M 0.14%
3,954,800
-234,793
-6% -$891K
MIST icon
108
Milestone Pharmaceuticals
MIST
$127M
$15M 0.14%
2,583,821
+90,712
+4% +$664K
SRPT icon
109
Sarepta Therapeutics
SRPT
$1.62B
$14.9M 0.14%
200,278
-338,771
-63% -$31.3M
SYRS
110
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$13.7M 0.13%
183,750
+27,500
+18% +$2.86M
TVTX icon
111
Travere Therapeutics
TVTX
$5.12B
$13.2M 0.12%
+528,100
New +$14.6M
MAPS
112
DELISTED
WM TECHNOLOGY INC A
MAPS
$12.9M 0.12%
+700,400
New +$14.7M
PCVX icon
113
Vaxcyte
PCVX
$7.7B
$12.8M 0.12%
648,774
+18,514
+3% +$466K
ALEC icon
114
Alector
ALEC
$171M
$12.3M 0.12%
611,478
-1,613,835
-73% -$28.9M
RLAY icon
115
Relay Therapeutics
RLAY
$3.96B
$12.1M 0.11%
350,000
– –
XFOR icon
116
X4 Pharmaceuticals
XFOR
$375M
$11.8M 0.11%
45,795
+9,579
+26% +$2.52M
DNTH icon
117
Dianthus Therapeutics
DNTH
$5.57B
$11.2M 0.11%
+59,316
New +$9.98M
ALXO icon
118
ALX Oncology
ALXO
$261M
$11.1M 0.1%
150,000
– –
IMDX
119
Insight Molecular Diagnostics
IMDX
$146M
$10.9M 0.1%
+105,000
New +$9.97M
OLK
120
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$10.8M 0.1%
+300,000
New +$10.1M
GYRE icon
121
Gyre Therapeutics
GYRE
$639M
$10.7M 0.1%
+282,480
New +$12.9M
NRIX icon
122
Nurix Therapeutics
NRIX
$2.46B
$9.33M 0.09%
300,000
– –
LRMR icon
123
Larimar Therapeutics
LRMR
$389M
$9.02M 0.08%
617,245
-269,315
-30% -$4.89M
ASLN
124
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$8.44M 0.08%
+63,000
New +$7.98M
HCAT icon
125
Health Catalyst
HCAT
$159M
$8.4M 0.08%
179,598
– –
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2021 Portfolio in Review

As of Q1 2021, OrbiMed held 188 positions worth $10.7B, down 6.4% from $11.4B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed deployed $511M of net new capital in Q1 2021, opening 39 new positions and adding to 39 existing holdings. Its largest new stake was Edgewise Therapeutics: 13,944,680 shares worth $453M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Prelude Therapeutics, an estimated $369M trimmed.

  • OrbiMed's largest Q1 2021 buy was Edgewise Therapeutics: 13,944,680 shares worth $453M.
  • OrbiMed added most to Merck in Q1 2021, an estimated $83M increase.
  • OrbiMed's biggest Q1 2021 reduction was Prelude Therapeutics, cutting an estimated $369M.
  • OrbiMed fully exited Prevail Therapeutics Inc. Common Stock in Q1 2021, selling an estimated $319M.
  • OrbiMed's ten largest holdings make up 33% of its $10.7B portfolio in Q1 2021.
  • OrbiMed opened 39 new positions and closed 30 in Q1 2021.
  • OrbiMed's portfolio value fell 6.4% quarter-over-quarter to $10.7B.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.